Table 1.
Demographic and clinical data
| Patient characteristics | Values | |
|---|---|---|
| Gender (n = 54) | ||
| Male | n = 38 | 70.4% |
| Female | n = 16 | 29.6% |
| Age (years, n = 54) | ||
| Mean age ± SD | 46.9 ± 13.4 | |
| Minimum | 20.0 | |
| Maximum | 80.0 | |
| Height (cm, n = 54) | ||
| Mean height ± SD | 175.1 ± 14.0 | |
| Minimum | 108.0 | |
| Maximum | 200.0 | |
| Body mass index, BMI (n = 54) | ||
| Average BMI ± SD | 32.6 ± 18.4 | |
| Median (lower quartile; upper quartile) | 30.6 (26.2; 33.2) | |
| Underweight (< 18.5) | n = 0 | 0.0% |
| Normal weight (18.5–24.9) | n = 11 | 20.4% |
| Overweight (25.0–29.9) | n = 15 | 27.8% |
| Obesity (> 30.0) | n = 28 | 51.8% |
| Waist (cm) | Male (n = 29) | Female (n = 11) |
| Mean ± SD | 103.6 ± 14.5 | 97.3 ± 16.6 |
| Normal (male, ≤ 94 cm; female, ≤ 80 cm) | 10.3% | 0.0% |
| Elevated (male, > 94 cm; female, > 80 cm) | 31.0% | 0.0% |
| Greatly increased (male, > 102; female, > 88 cm) | 58.7% | 100.0% |
| Hips (cm) | Male (n = 29) | Female (n = 11) |
| Mean ± SD | 106.1 ± 10.2 | 102.0 ± 7.2 |
| Waist to hip ratio, WHP | Male (n = 29) | Female (n = 11) |
| Normal (male, < 0.90; female, < 0.85) | 20.7% | 18.2% |
| Elevated (male, ≥ 0.90; female, ≥ 0.8) | 79.3% | 81.8% |
| Anamnesis | Values | |
| Comorbidity (n = 54) | ||
| With concomitant illness | n = 19 | 35.2% |
| Without concomitant illness | n = 35 | 64.8% |
| Duration of psoriasis (n = 46) (years) | ||
| Mean ± SD | 18.6 ± 12.7 | |
| Median (lower quartile; upper quartile) | 18.2 (6.6; 27.7) | |
| Up to 10 years | n = 14 | 30.4% |
| 10 to < 20 years | n = 10 | 21.7% |
| 20 to < 30 years | n = 12 | 26.1% |
| 30 to < 40 years | n = 8 | 17.4% |
| 40 to < 50 years | n = 1 | 2.2% |
| ≥ 50 years | n = 1 | 2.2% |
| Other manifestation of psoriasis (n = 54) | ||
| No | n = 47 | 87.0% |
| Yes | n = 7 | 13.0% |
| Nail involvement | n = 4 | 7.3% |
| Psoriatic arthritis | n = 0 | 0.0% |
| Inverse psoriasis | n = 2 | 3.6% |
| Pustular psoriasis | n = 1 | 1.8% |
| Psoriasis capitis | n = 1 | 1.8% |
| Previous systemic/UV light therapy (n = 54) | ||
| No | n = 3 | 5.6% |
| Yes | n = 51 | 94.4% |
| Fumaric acid ester | n = 0 | 0.0% |
| Methotrexate | n = 40 | 74.1% |
| UV therapy | n = 6 | 11.1% |
| Apremilast | n = 10 | 18.5% |
| Leflunomide | n = 0 | 0.0% |
| Cyclosporine A | n = 19 | 35.2% |
| Retinoids | n = 30 | 55.6% |
| Systemic steroids | n = 0 | 0.0% |
| Previous biologics/biosimilar therapy (n = 54) | ||
| No | n = 26 | 48.2% |
| Yes | n = 28 | 51.8% |
| Secukinumab | n = 8 | 14.8% |
| Adalimumab | n = 17 | 31.5% |
| Ustekinumab | n = 6 | 11.1% |
| Etanercept | n = 9 | 16.7% |
| Guselkumab | n = 0 | 0.0% |
| Ixekizumab | n = 4 | 7.4% |
| Infliximab | n = 2 | 3.7% |
| Efalizumab | n = 3 | 5.6% |
| Other | n = 4 | 7.4% |
n number of patients, SD standard deviation, UV ultraviolet